Stock Price Quote

BAL PHARMA LTD.

NSE : BALPHARMABSE : 524824ISIN CODE : INE083D01012Industry : Pharmaceuticals & DrugsHouse : Private
BSE119.15-3.55 (-2.89 %)
PREV CLOSE ( ) 122.70
OPEN PRICE ( ) 117.20
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 8008
TODAY'S LOW / HIGH ( )117.20 124.50
52 WK LOW / HIGH ( )63.4 132.2
NSE119.30-3.25 (-2.65 %)
PREV CLOSE( ) 122.55
OPEN PRICE ( ) 124.90
BID PRICE (QTY) 119.30 (290)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 36271
TODAY'S LOW / HIGH( ) 116.00 124.90
52 WK LOW / HIGH ( )63.35 132.45
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1987
Management Info
- Chairman Shailesh Siroya - Managing Director
Registered Office

Address #21&22, Bommasandra Industrial Area,Anekal Taluk, ,
Bengaluru,
Karnataka-560099

Phone 080 41570811 / 13 / 19

Email investor@balpharma.com

Website www.balpharma.com

Registrars Details
Link Intime India Pvt Ltd.
C-101, 1st Floor,247 Park, Lal Bahadur Shastri Marg,Vikhroli West,Mumbai
Listing : BSE, NSE, MCX

NEWS

14Feb Bal Pharma informs about press release
Bal Pharma has informed that it enclosed copies of the newspaper adverti..
28Dec Bal Pharma informs about closure of tr
Pursuant to the Code of Conduct of the Company and as per the amended pr..
21Nov Bal Pharma informs about newspaper pub
Bal Pharma has informed about newspaper publication of the notice issued..
14Aug Bal Pharma informs about newspaper adv
Bal Pharma has submitted newspaper advertisements of abridged Un-audited..
23Feb Bal Pharma informs about details of lo
Bal Pharma has informed that it submitted the intimation received from R..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit12.5761.2699999999999
Gross Profit 16.74 85.4999999999999
Operating Profit 78.86281.87
Net Sales 814.953030.99

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2145.85 (4.89%)
M.Cap ( in Cr)1325.71
Neuland Laboratories (BSE)
peergroup  7118.95 (0.84%)
M.Cap ( in Cr)9133.53
Alembic Pharma (BSE)
peergroup  1047.25 (4.19%)
M.Cap ( in Cr)20585.07
Glaxosmithkline Phar (BSE)
peergroup  2295.10 (1.75%)
M.Cap ( in Cr)38880.38
Glenmark Pharma (BSE)
peergroup  893.90 (3.64%)
M.Cap ( in Cr)25224.80

Shareholding Pattern

PROMOTERS 51.23%
NON-INSTITUTION 48.64%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Bal Pharma Ltd.

Bal Pharma Ltd. was incorporated in the year 1987. Its today's share price is 119.15. Its current market capitalisation stands at Rs 188.36 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3030.99 Cr and Total Income of Rs.3052.54 Cr. The company's management includes Abdul Basith, HS Venkatesh, Jatish Sheth, Nicloa Neeladri, CV Srinivas, Kotian Chittananda Damodar, Himesh Virupakshaya, Shailesh Siroya.

It is listed on the BSE with a BSE Code of 524824 , NSE with an NSE Symbol of BALPHARMA and ISIN of INE083D01012. It's Registered office is at #21&22, Bommasandra Industrial Area,Anekal Taluk, Bengaluru-560099, Karnataka. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are NSVM & Associates, SSJNB & Co, TD Jain & DI Sakaria, TD Jain & Dl Sakria

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.